Table 1.

Baseline clinical and laboratory data of patients with IgA nephropathy

CharacteristicsMean±SD or Median (IQR)
Baseline
 Age, yr35.6±12.4
 Sex, men/women238 (54.3%)/200 (45.7%)
 24-h UPE, g/d1.60 (0.88–3.13)
  <0.319/438 (4.3%)
  0.3–0.99110/438 (25.1%)
  1.0–2.99194/438 (44.3%)
   ≥3.0115/438 (26.3%)
 ACR, mg/g460.1 (241.3–743.4)
  <3014/438 (3.2%)
   ≥30424/438 (96.8%)
 Protein-to-creatinine  ratio, g/g0.71 (0.29–1.59)
  <0.275/438 (17.1%)
   ≥0.2363/438 (82.9%)
 eGFR, ml/min per 1.73 m282.1±27.4
 CKD stagesa
  1191 (43.6%)
  2147 (33.6%)
  383 (18.9%)
  417 (3.9%)
 SBP, mmHg124±16
 DBP, mmHg79±12
 Oxford classificationb
  M1358 (82.3%)
  E1214 (49.2%)
  S1296 (68.0%)
  T1/T2112 (25.7%)/53 (12.2%)
 Extracapillary proliferation225 (51.4%)
Follow-up
 Follow-up interval, mo37.0 (22.0–58.0)
 Therapy
  ACE inhibitors or ARBs424 (96.8%)
  Prednisone and any other  immunosuppressive  agents  (cyclophosphamide,  MMF, or others)175 (40.0%)
  • IQR, interquartile range; UPE, urinary protein excretion; ACR, albumin-to-creatinine ratio; SBP, systolic BP; DBP, diastolic BP; M1, Oxford classification for mesangial hypercellularity >0.5; E1, Oxford classification for presence of endocapillary proliferation; S1, Oxford classification for presence of segmental glomerulosclerosis/adhesion; T1/T2, Oxford classification for severity of tubular atrophy/interstitial fibrosis of 26%–50% and >50%; ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; MMF, mycophenolate mofetil.

  • a CKD stages 1–4 were divided by eGFR≥90, =60–89, =30–59, and =15–29 ml/min per 1.73 m2, respectively, according to the Kidney Disease Outcomes Quality Initiative.

  • b Oxford classification was developed by the Working Group of the International IgA Nephropathy Network and the Renal Pathology Society.